Company news

Vir Biotechnology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 1, 2023

Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

October 29, 2023

Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference

October 11, 2023

Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023

October 10, 2023

Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023

October 4, 2023

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

October 2, 2023

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

September 19, 2023

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 2, 2023

Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023

July 25, 2023

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

July 19, 2023

Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

June 28, 2023

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

June 23, 2023

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023

June 6, 2023

Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

June 4, 2023

Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

May 16, 2023

Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

May 14, 2023

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

May 10, 2023

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 3, 2023

Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference

May 2, 2023

Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention

May 1, 2023

Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

March 7, 2023

Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

February 27, 2023

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)

February 21, 2023

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

February 15, 2023

Vir Biotechnology Appoints Sung Lee as Chief Financial Officer

February 15, 2023

Vir Biotechnology Announces Amended Collaboration Agreement with GSK

February 12, 2023

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

January 24, 2023

Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

December 20, 2022

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

November 15, 2022

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection

November 5, 2022

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 2, 2022

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022

October 30, 2022

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

October 27, 2022

Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

October 17, 2022

Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

October 10, 2022

Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats

October 3, 2022

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

September 21, 2022

Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 8, 2022

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022

July 20, 2022

Vir Biotechnology Announces Transition of Chief Scientific Officer

July 13, 2022

Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

June 24, 2022

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022

June 7, 2022

Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details

May 17, 2022

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 4, 2022

Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day

April 26, 2022

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022

April 20, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 30 decks. Every deck is listed under its year.